QUANTUM BIOPHARMA-B SUB VOT (QNTM) Stock Price, Forecast & Analysis
USA - NASDAQ:QNTM - CA74764Y2050 - Common Stock
QNTM Key Statistics, Chart & Performance
The current stock price of QNTM is 7.69 USD. In the past month the price decreased by -48.97%. In the past year, price increased by 49.03%.
QNTM Latest News, Press Relases and Analysis
QNTM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.52 | 968.11B | ||
| JNJ | JOHNSON & JOHNSON | 18.81 | 470.23B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.12B | ||
| PFE | PFIZER INC | 8.06 | 146.63B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.41 | 98.98B | ||
| ZTS | ZOETIS INC | 19.11 | 53.70B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 23.17B | ||
| VTRS | VIATRIS INC | 4.68 | 12.72B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 10.92B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.08 | 7.98B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.86B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.90B |
Related stock screener links
About QNTM
Company Profile
Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Company Info
QUANTUM BIOPHARMA-B SUB VOT
55 University Ave. , Suite 1003
TORONTO ONTARIO CA
Employees: 10
Phone: 14168548884
QUANTUM BIOPHARMA-B SUB VOT / QNTM FAQ
Can you describe the business of QUANTUM BIOPHARMA-B SUB VOT?
Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
What is the current price of QNTM stock?
The current stock price of QNTM is 7.69 USD. The price decreased by -7.68% in the last trading session.
Does QNTM stock pay dividends?
QNTM does not pay a dividend.
How is the ChartMill rating for QUANTUM BIOPHARMA-B SUB VOT?
QNTM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for QNTM stock?
7 analysts have analysed QNTM and the average price target is 32.72 USD. This implies a price increase of 325.46% is expected in the next year compared to the current price of 7.69.
Can you provide the number of employees for QUANTUM BIOPHARMA-B SUB VOT?
QUANTUM BIOPHARMA-B SUB VOT (QNTM) currently has 10 employees.
What is the outstanding short interest for QUANTUM BIOPHARMA-B SUB VOT?
The outstanding short interest for QUANTUM BIOPHARMA-B SUB VOT (QNTM) is 0.81% of its float.
QNTM Technical Analysis
QNTM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QNTM Forecast & Estimates
7 analysts have analysed QNTM and the average price target is 32.72 USD. This implies a price increase of 325.46% is expected in the next year compared to the current price of 7.69.